Large molecular weight TSH-beta: the sole immunoactive form of TSH-beta in certain human sera.
The beta subunit of TSH (TSH-beta) usually cannot be detected (less than 0.2 ng/ml) in the serum of normal individuals, whereas patients with primary hypothyroidism exhibit elevated TSH-beta levels (0.2-9.3 ng/ml), which increase further after the administration of TRH. Two patients were found to have large TSH-beta as the only form of serum TSH-beta immunoactivity. Patient A was a euthyroid woman with a goiter; TSH and alpha subunit levels were normal (1 microU/ml and 0.6 ng/ml, respectively); TSH-beta was elevated (8-24 ng/ml). Patient B was a woman with borderline hypothyroidism, an elevated serum TSH level (19 microunits/ml), a normal serum alpha level (2.4 ng/ml), and an elevated serum TSH-beta level (1.8-3.6 ng/ml). Dilutions of both patients' sera demonstrated nonparallelism of their serum TSH-beta to standard TSH-beta. The elevated serum TSH-beta levels did not increase after TRH, although TSH and alpha subunit increased appropriately. After the administration of dexamethasone or T4 to patient B, serum TSH-beta did not decrease, although TSH and alpha decreased. Gel chromatography and rechromatography of the patients' sera on a Sephadex G-100 column showed elution of all TSH-beta immunoactivity in or near the void volume (Vo; greater than 150,000 mol wt), whereas sera of hypothyroid patients demonstrated less than 7% of TSH-beta immunoactivity in the Vo. By chromatography on a Sephadex G-200 column, the TSH-beta immunoactivity had a 160,000 mol wt in patient A and 200,000 mol wt in patient B. Incubation of labeled or unlabeled TSH-beta with serum or gamma-globulin fractions from both patients resulted in no significant increase in the binding of TSH-beta to serum components, as determined by both gel chromatography and precipitation with antihuman gamma-globulin. Large TSH-beta was stable after incubation with 6 M guanidine. Ribonuclease failed to affect the large TSH-beta. Inter-chain disulfide bonding was not demonstrated in large TSH-beta after treatment with three different reducing agents (mercaptoethanol, sodium sulfite, and dithioerythritol). Treatment with trypsin did not convert the large TSH-beta immunoactivity to standard TSH-beta. These experiments demonstrated that the large TSH-beta immunoactivity was not caused by binding of TSH-beta to an immunoglobulin or other serum protein or by aggregation of TSH-beta molecules. The significance of these apparently covalently bonded large forms of TSH-beta immunoactivity is not yet known; the presence of small amounts of a large molecular weight form in the serum of hypothyroid patients and normal pituitary extracts raises the possibility that they may be components of normal TSH biosynthesis or represent posttranslational modifications.
D000328:Adult; D005260:Female; D015292:Glycoprotein Hormones, alpha Subunit; D006111:Graves Disease / Q000532:radiotherapy; D006801:Humans; D007037:Hypothyroidism / Q000097:blood* / Q000209:etiology; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D007700:Kinetics; D008970:Molecular Weight; D010446:Peptide Fragments / Q000097:blood*; D011863:Radioimmunoassay; D013972:Thyrotropin / Q000097:blood*; D013973:Thyrotropin-Releasing Hormone
D015292:Glycoprotein Hormones, alpha Subunit; D007457:Iodine Radioisotopes; D010446:Peptide Fragments; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin